Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh ( (AU:RMD) ) has issued an update.
ResMed Inc.’s CEO, Michael J. Farrell, executed transactions involving the company’s common stock under a pre-established Rule 10b5-1 plan. This plan allows for the planned sale or purchase of securities, providing a structured approach to managing stock transactions. The transactions involved the acquisition and subsequent sale of 8,009 shares, reflecting strategic financial management by the company’s leadership. These actions are part of a broader strategy to optimize stock holdings and align with corporate governance practices, potentially impacting stakeholder perceptions and market dynamics.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$37.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
More about Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh
ResMed Inc. operates in the healthcare industry, focusing primarily on the development, manufacturing, and distribution of medical equipment related to sleep disorders, respiratory care, and connected health solutions. The company is known for its innovative products that improve the quality of life for patients with sleep apnea and other chronic respiratory conditions.
Average Trading Volume: 1,001,886
Technical Sentiment Signal: Buy
Current Market Cap: A$57.56B
See more insights into RMD stock on TipRanks’ Stock Analysis page.